Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9318156 | 0.78 | TP53 (0.41) | — | |
| Hydrochloric Acid SCHEMBL3853452 | 0.76 | TP53 (0.39) | — | |
| SCHEMBL27648132 | 0.71 | CA12 (0.42) | NPC1 | |
| SCHEMBL27934351 | 0.71 | TSHR (0.42) | HTTNPC1RAB9A | |
| SCHEMBL27934350 | 0.70 | CYP3A4 (0.44) | — | |
| SCHEMBL27483908 | 0.70 | CYP3A4 (0.41) | — | |
| SCHEMBL27279362 | 0.69 | KCNN4 (0.36) | HTTNPC1RAB9A | |
| SCHEMBL27969154 | 0.69 | TSPO (0.35) | — | |
| Bromide SCHEMBL9064446 | 0.69 | ALDH1A1 (0.47) | — | |
| Bromide SCHEMBL9374239 | 0.68 | SIGMAR1 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1149885-B1 | Cyclohexane derivatives, liquid crystal compositions comprising the same and liquid crystal display devices | CHISSO CORP (JP) | 2004-09-22 | — | — | EP | disclosed |
| US-6500503-B2 | Liquid crystal compound containing fluoro substituted benzene ring | CHISSO CORPORATION (JP) | 2002-12-31 | — | — | US | disclosed |
| US-20020066888-A1 | Cyclohexane derivatives, liquid crystal compositions comprising the same and liquid crystal display devices | JNC PETROCHEMICAL CORPORATION (JP) | 2002-06-06 | — | — | US | disclosed |
| EP-1149885-A1 | Cyclohexane derivatives, liquid crystal compositions comprising the same and liquid crystal display devices | CHISSO CORPORATION (JP) | 2001-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020066888-A1 | Cyclohexane derivatives, liquid crystal compositions comprising the same and liquid crystal display devices | SCO2, KLK1, HCN2 | HTT 4568/4885NPC1 795/4885RAB9A 4501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.